Łukasz Puchała, Stanisław Maksymowicz

Directions of searching for new drugs for ALS
2019-06-03

Amyotrophic lateral sclerosis is a severe and incurable neurodegenerative disease with poorly understood etiology. The introduction of two drugs riluzol and edaravone did not solve the patient’s problem, because the clinical benefits are insufficient. Current clinical trials assess the extremely diverse range of drugs, in addition to being considered for the possibility of biological therapies such as stem cell administration. Due to the characteristics of the disease and the limited number of patients, an important element of the designed therapies is the use of orphan drug.

Keywords: Amyotrophic lateral sclerosis, ALS, clinical trials, edaravone, clinical pharmacy.

© Farm Pol, 2019, 75(5): 247–250